As first immune responders, neutrophils are essential mediators of host defense, and also contribute to chronic pathologic inflammation at the crossroads of innate and adaptive immunity. In this review, we will highlight the current understanding of the role of neutrophils in pediatric rheumatology, with a focus on juvenile idiopathic arthritis (JIA) and lupus.
INTRODUCTION
Neutrophils are key mediators of the innate immune response and are the first responders to sites of infection and tissue damage. Once at the site of infection, neutrophils play a critical role in host defense through phagocytosis, degranulation, and secretion of antimicrobial factors, production of reactive oxygen species (ROS), and release of neutrophil extracellular traps (NETs) [1, 2] . Although the primary function of neutrophils is to protect the host from pathogens, the influx of neutrophils to a tissue site can contribute directly to tissue damage and the progression to chronic inflammation. Neutrophils mediate a pro-inflammatory response to tissue damage or infection by releasing cytokines that recruit and activate other immune cells, and lead to the activation of adaptive immunity. Classically considered an early responder that dies at the site of inflammation, new findings suggest that neutrophils are longer-lived cells with substantial plasticity. Indeed, there has been increased interest in the role of neutrophils in autoimmune disease.
As sentinels of the immune response in autoimmune arthritis, neutrophils contribute directly to joint damage and also pave the way for adaptive immunity by secreting cytokines and other factors that enhance antigen presentation. Neutrophils also secrete plasma B-lymphocyte stimulator (Blys) that promotes B-cell activation [3] . In the tissue, neutrophils cause extensive injury via the release of proteases and ROS, and thus could release potential autoantigens such as extracellular matrix proteins filaggrin and aggrecan [3, 4] . Upon activation, neu-trophils also can die in a process called NETosis in which chromatin is extruded to form a nuclear extracellular trap. In addition to having an important role in the innate immune response against pathogens, NETs have also been implicated in the development of autoimmunity. Specifically, NETs display some of the citrullinated antigens that are known to be targets of anticitrullinated protein antibodies (ACPAs) found in rheumatoid arthritis (RA) [5] . Chromatin NETs are an obvious source of nuclear material, which could also serve as an autoantigen.
Traditionally, neutrophils have been thought of as short-lived cells that die at sites of inflammation; however, increasing evidence suggests that neutrophils can be long-lived and can also 'reverse' migrate away from sites of inflammation. Imaging studies [6, 7] in zebrafish and more recently in mice have demonstrated that neutrophils not only migrate to damaged tissue but also can reverse migrate back into the vasculature. In support of this idea, previous studies have suggested that there is an increased presence of (C-X-C motif) receptor 1 low/CD54 high 'reverse' transmigrated neutrophils in the blood of patients with systemic inflammation [8] . These 'inflammation-experienced' neutrophils that re-enter the vasculature may have diverse functions including regulating other immune cells to mediate systemic inflammation and autoimmunity [8] . However, there remains a significant gap in understanding how neutrophils modulate the development and progression of autoimmune disease. Here, we review what is currently known about the role of neutrophils in pediatric autoimmune disease, with a focus on juvenile idiopathic arthritis (JIA) and lupus.
AUTOINFLAMMATORY DISEASE IN CHILDHOOD
Rheumatic diseases of children can typically be divided into autoimmune and autoinflammatory disorders. Although neutrophil infiltration into tissues is often present in both classes of disease, autoinflammatory diseases typically are due to apparently unprovoked activation of the innate immune system, whereas autoimmune diseases are often driven by autoreactive T cells and autoantibodies. Herein we will not discuss the substantial progress that has been made in defining the molecular basis of monogenic autoinflammatory diseases, and refer the reader to several excellent reviews [9, 10] . However, it is important to note that the discovery of these molecular mechanisms has provided new insight into how the innate immune system works and has helped provide a framework for further understanding of the innate immune response in autoimmune disease. Notably, the recent discovery of NOD-like receptor CARD-domain containing protein 4 (NLRC4) mutations in autoinflammation highlighted the concept that neutrophils -not T cells -can be the primary source of interleukin (IL)-17 downstream of IL-1b signaling [11 & ]. It is also important to consider that some 'autoimmune' diseases like Behcet's disease or systemic JIA may be better categorized as autoinflammatory diseases, highlighting the overlap between these disease categories. Indeed, pediatric patients who present with 'autoimmune' disease at a young age often have inherited immune deficiencies. For instance, children may develop manifestations of inflammatory bowel disease with neutrophil inflammation due to primary defects in innate immunity, including chronic granulomatous disease or mutations in IL-10 or the IL-10 receptor (reviewed in [12] ).
NEUTROPHILS IN JUVENILE IDIOPATHIC ARTHRITIS
Juvenile idiopathic arthritis refers to a group of diseases with onset prior to 16 years of age, unified by the presence of arthritis lasting at least 6 weeks without other identified cause. Taken together as a group, JIA constitutes the most common chronic autoimmune disease of childhood. The 2001 International League of Associations for Rheumatology (ILAR) classification criteria subdivide JIA into seven categories based on the number of joints that are affected and systemic involvement: oligoarticular JIA, rheumatoid factor-negative polyarticular JIA (more than four joints), rheumatoid factor-positive JIA, systemic JIA, psoriatic JIA, enthesitis-related arthritis (ERA), and 'undifferentiated' (not meeting category criteria or fulfilling >1 category). Although
KEY POINTS
The role of neutrophils in pediatric rheumatologic disease is vastly understudied, but garnering increasing interest.
Neutrophils from JIA patients display abnormal gene expression patterns.
The S100A calgranulin proteins secreted by activated neutrophils have potential as biomarkers, particularly in identifying subclinical disease and predicting flares.
Neutrophil NETosis may provide autoantigen and trigger type I IFN in lupus, but the role of NETassociated ROS production remains controversial.
In lupus, enhanced neutrophil apoptosis has been described, with unclear pathogenic implications.
Neutrophils in pediatric autoimmune disease Huttenlocher and Smith the different JIA categories share some pathogenic mechanisms and treatment approaches, both the heterogeneous clinical characteristics and underlying genetics suggest the subtypes are distinct entities and the role of neutrophils in pathogenesis likely differs by JIA subtype. Although neutrophils are the most abundant cell type found in JIA synovial fluid, the study of their role in JIA has been limited. Two major advances have been the study of neutrophil cell-intrinsic differences in JIA and the potential use of neutrophil-derived S100A proteins as biomarkers.
Oligoarticular and rheumatoid factor-negative polyarticular JIA are commonly considered as 'autoimmune diseases' related to numerous factors, including the linkage with specific Human leukocyte antigen (HLA) haplotypes, as well as the abundant CD4 þ CD45RO þ memory lymphocytes of the Th1 subtype in synovial fluid [13,14 & ,15]. Genomewide association studies (GWAS) [14 & ,16] of regions outside the Major histocompatibility complex have identified associations with PTPN22, PTPN2, STAT4, IL2RA, and other loci that overlap with classic autoimmune diseases including adult RA, type I diabetes, and multiple sclerosis. However, the purely 'autoimmune' model does not take into account the complex interweaving of adaptive and innate immunity that occurs in JIA. Also, recent studies of JIA-associated noncoding genetic regions examining histone acetylation 'enhancer' marks revealed shared active regions in CD4 T cells and neutrophils [17 & ]. These results suggest that the genetic regions identified by GWAS could impact multiple immune cell types, including neutrophils.
Gene expression studies in neutrophils from rheumatoid factor-negative polyarticular JIA patients have revealed dysregulated clusters of IL-8 and interferon (IFN)g-regulated genes [18] . Other altered genes in neutrophils related to calcium flux and superoxide production have been reported. These gene expression abnormalities distinguished JIA and healthy controls, but not active and inactive disease, suggesting cell-intrinsic defects [18] . Further, like adult RA, there is evidence for chronic activation of peripheral neutrophils in pediatric patients with polyarticular disease. S100A proteins (also referred to as calgranulins) are zinc and calcium-binding proteins that constitute up to 50% of the cytosolic protein in phagocytes. Neutrophils and early differentiating monocytes produce S100A8, S100A9, and the S100A8/S100A9 (MRP8/MRP14) heterodimer also known as calprotectin. S100A12 (EN-RAGE, calgranulin C) is predominantly produced by activated neutrophils. Upon binding the receptors for advanced glycation end products (RAGE), S100A proteins activate endothelial cells, inducing expression of adhesion molecules and chemoattractants, and thus increasing leukocyte recruitment. Calprotectin also triggers Toll-like receptor (TLR)4, promoting secretion of pro-inflammatory cytokines such as IL-6, IL-1b, and tumor necrosis factor (TNF)a [19] . Related to the intense neutrophil activation in inflamed joints, levels of calprotectin and S10012A rise to very high levels within joints, but also increased serum levels 5-10-fold higher than controls have been reported [12] . Elevated serum calprotectin is not specific to JIA, and can be found in Kawasaki's disease and sepsis [20, 21] . However, the potential use of S100A serum levels as an activity biomarker has generated excitement in the field. Levels go up with active disease, and down with systemic therapy (methotrexate or etanercept) and with intra-articular steroid injections [21] . Elevated serum calprotectin was more specific than clinical data, inflammatory cytokine levels, and standard laboratory parameters in predicting response to methotrexate [22] . Most intriguingly, increased calprotectin and S100A12 levels appear to herald a disease flare. In a prospective study [23] , S100A12 was the best single predictor of disease flare after therapy withdrawal. Reliability of an activity-related biomarker that could reveal subclinical disease or predict flares would represent significant progress for therapeutic decision-making.
Rheumatoid factor-positive JIA, accounting for less than 5% of the patients, is generally thought to mark the early onset of adult RA, given patterns of joint involvement, ACPA, and rheumatoid factor autoantibodies, and persistence into adulthood. Neutrophils have a unique niche in rheumatoid factor-positive diseases compared to other JIA subtypes: the capacity of neutrophils to extrude NETs containing citrullinated proteins may contribute to the generation of pathogenic ACPAs. The role of neutrophils in RA and NET formation has been extensively reviewed elsewhere and will not be further discussed [24] .
NEUTROPHILS IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Calgranulin levels are of potentially even greater interest in systemic JIA, where neutrophils may be primary effectors. The prominent systemic features, including spiking fevers, rash, hepatosplenomegaly, and serositis, distinguish systemic JIA from other subtypes. These clinical features and the underlying genetics (HLA associations are conspicuously absent) place this disease firmly into the 'autoinflammatory' category. IL-1 and IL-6 appear to play the dominant role in producing disease manifestations, as attested to by IL-1 gene signatures, elevated IL-6 levels, and response to corresponding cytokine blockade [15] . During active disease, patients can develop neutrophilia, to levels observed in leukemia. Perhaps related to this intense neutrophil activation, levels of S100A12 soar to approximately 70Â control and 10Â greater than other forms of JIA. Indeed this incredible elevation distinguishes systemic JIA from other forms of JIA, as well as sepsis. Levels of S100A12 were 10-fold higher in joint fluid than in serum, and like calprotectin, serum S100A12 levels were predictive of flares [21] .
NEUTROPHILS IN SPONDYLOARTHRITIS
Calprotectin levels are also increased in ERA, and respond to treatment, but elevations are less than reported in other subtypes (2.5-fold vs. controls), consistently with a smaller role for neutrophils in spondyloarthritis [25] . Multiple studies in spondyloarthritis pathogenesis have highlighted the importance of the IL-23/IL-17 cytokine pathway, and this topic has recently been reviewed [26] . Interestingly, evaluation of the cellular source of IL-17 production within biopsies supports an unexpected role for the innate immune system: in a study by Appel et al. [27] of spinal facet joints, IL-17 was predominantly produced by MPOþ cells and CD15þ neutrophils (as opposed to T cells). This study [26] and others suggest innate immune cells, including neutrophils, may be the predominant producers of pathogenic IL-17 in spondyloarthritis.
NEUTROPHILS IN LUPUS
Lupus is a systemic autoimmune disease characterized by autoantibody formation with the deposition of immune complexes in tissues and multiorgan involvement. Although substantial focus has been on the role of the adaptive immune system in lupus pathogenesis, recent studies have brought attention to the role of neutrophils in lupus (reviewed in [28, 29] ). The role of neutrophils in lupus is likely different than in JIA, where neutrophils are thought to traffic to the joint and create local inflammation and damage [28] . In contrast to JIA where neutrophils are generally 'activated', there is evidence that neutrophils from lupus patients have impaired activation with reduced chemokine-induced chemotaxis and oxidative burst [28, 29] . Moreover, lupusassociated variations in the integrin, alpha M (complement component 3 receptor 3 subunit) gene that encode the b-chain of the leukocyte integrin MAC1 result in impaired leukocyte adhesion and phagocytosis (reviewed in [30] ). However, lupus neutrophils can also have an activated phenotype, in particular, in the vasculature where neutrophils contribute to vascular damage and the development of vasculitis [28, 29, 31, 32] . One possible reason for the discrepancy about neutrophils in lupus is the presence of a subset of neutrophils in the peripheral blood called low-density granulocytes (LDGs), which have increased NET formation and enhanced ability to stimulate plasmacytoid dendritic cells [33] .
Neutrophil NETs have been an area of significant focus in understanding the pathogenesis of lupus [33] . In pediatric lupus neutrophil NETs can activate plasmacytoid dendritic cells to secrete type I interferon, a major cytokine implicated in lupus [34] . Further, neutrophils that form NETs can cause endothelial cell damage in lupus [32] . NETs have also been thought to be a source of autoantigens in lupus, similarly to RA [28] , but there are conflicting data for this idea [29] . In mouse models, neutrophils do not make NETs in lupus-prone mice deficient in the Nox2, despite having worsened disease [35] . Genetic variations in NADPH subunit Neutrophil cytosolic factor 2 (NCF2) have been linked to increased risk for lupus in humans [36] . Interestingly, NCF2 variations associated with lupus risk result in reduced phagocyte ROS production, providing further evidence that ROS production is not necessarily pro-inflammatory in lupus [37 & ]. Further studies will be needed to dissect the immunomodulatory effects of phagocyte ROS signaling in the context of lupus [36] . Alternatively, neutrophils from pediatric patients with lupus have increased apoptosis that can also provide a source of autoantigen in lupus. In particular, serum from pediatric lupus patients induces neutrophil apoptosis, and this may be abrogated by treatment with Granulocyte-macrophage colony-stimulating factor (GM-CSF), indicating potential therapeutic benefit of GM-CSF in patients with lupus [38] . Thus, there is conflicting evidence regarding the function of neutrophils in lupus, although, to date, much of the evidence supports a key role in disease pathogenesis. Taken together, more work is needed to clearly define the role of neutrophils in lupus, including dissecting the pro-inflammatory and immunomodulatory effects of neutrophils.
CONCLUSION
There are a few studies that report on the role of neutrophils in pediatric autoimmunity; however, there is recent growing interest in this area. For example, although neutrophils are the most common cells in JIA synovial fluid, their role in pathogenesis is greatly understudied. Studies of neutrophils in oligo and polyarticular JIA reveal intrinsic activity-independent abnormalities in gene expression. Circulating evidence of neutrophil activation, both calprotectin and S100A12, appear to be very promising biomarkers for overt and subclinical disease activity in JIA. More prospective studies regarding the practical application of these potential 'neutrophil' biomarkers are needed both in the context of JIA and pediatric lupus. The role of NET formation -a current area of controversy in lupus pathogenesis -requires further elucidation. Distinct activated neutrophil subsets and altered apoptosis have been described in lupus. More information is needed regarding how the unique neutrophil characteristics described in JIA and lupus translate into altered function in pediatric autoimmune disease and ultimately disease pathogenesis and treatment.
